Search - tctmd.com

Displaying 241 - 260 of 280

Sort: Relevancy | Date

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Daily News

TCTMD’s Top 10 Most Popular News Stories From 2011

Jason Kahn

March 08, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

EVOLVE Published: Bioabsorbable EES Matches Permanent-Polymer Version

February 21, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

Presentation TCT 2012

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Presenter: SunWon Kim, Seung Woon Rha, Byoung Geol Choi, Amro Elnagar, Sung Il Im, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

January 03, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Presenter: Kyounghoon Lee, Tae Hoon Ahn, Soon Yong Suh, Woong Chol Kang, Seung Hwan Han, Eak Kyun Shin

January 03, 2012

Presentation TCT 2012

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

Presenter: Jose M. De la Torre Hernandez, Dae-Hyun Lee, Tamara Garcia Camarero, Piedad Lerena, Gonzalo Martin Gorria, Fermin Sainz Laso, Javier Zueco

January 03, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Industry News

Advertisement

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

TCTMD’s Top 10 Most Popular News Stories From 2011

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

EVOLVE Published: Bioabsorbable EES Matches Permanent-Polymer Version

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content